While clinical trials and real-world studies have not confirmed an increased risk, comparative post-marketing analyses across all anti-obesity agents are scarce.<h4>Aim</h4>To compare disproportional reporting of suicidality-related adverse events among GLP-1/dual incretin versus non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System (FAERS).<h4>Method</h4>We conducted a retrospective disproportionality study using FAERS (January 2012-February 2025). Here, GLP1R is linked to Obesity.